PECCI, FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 673
EU - Europa 175
AS - Asia 83
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 976
Nazione #
US - Stati Uniti d'America 673
IT - Italia 64
IE - Irlanda 46
CN - Cina 40
SG - Singapore 37
SE - Svezia 36
CI - Costa d'Avorio 33
MA - Marocco 10
GB - Regno Unito 9
DE - Germania 6
FI - Finlandia 5
IN - India 5
UA - Ucraina 3
BE - Belgio 2
RU - Federazione Russa 2
EU - Europa 1
GR - Grecia 1
KR - Corea 1
NL - Olanda 1
VE - Venezuela 1
Totale 976
Città #
Chandler 118
Des Moines 79
Ashburn 59
Boardman 53
Fairfield 44
Dublin 42
New York 40
Abidjan 33
Turin 19
Seattle 18
Wilmington 18
Singapore 17
Woodbridge 16
Ann Arbor 14
Lawrence 13
Princeton 13
Houston 12
San Diego 12
Washington 12
Cambridge 9
San Mateo 9
Jacksonville 7
Los Angeles 7
Guangzhou 6
Ancona 5
Pune 5
Redmond 5
Arnold 4
Beijing 4
Fermignano 4
Helsinki 4
Tolentino 4
Wuhan 4
Dallas 3
Santa Clara 3
Brussels 2
Centro 2
Civitanova Marche 2
Fabriano 2
Falls Church 2
London 2
Parma 2
Shenzhen 2
Zhengzhou 2
Acton 1
Amsterdam 1
Bolton 1
Brandenburg 1
Chiswick 1
Clifton 1
Falconara Marittima 1
Foshan 1
Genzano di Roma 1
Islington 1
Jiaxing 1
Kilburn 1
Limido Comasco 1
Milan 1
New Bedfont 1
Phoenix 1
Qingdao 1
Quanzhou 1
Saint Petersburg 1
Seoul 1
Shanghai 1
Stockholm 1
Totale 755
Nome #
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 96
Electrolyte disorders in cancer patients: a systematic review 87
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 84
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 75
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 71
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 65
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 64
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 63
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 59
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 50
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 40
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 40
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 35
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 31
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 27
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 24
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 21
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 21
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives 21
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 19
Non-small-cell lung cancer: how to manage EGFR-mutated disease 10
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 8
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 5
Totale 1.016
Categoria #
all - tutte 7.324
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.324


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 1 3
2020/2021121 0 3 28 18 14 0 0 7 8 7 17 19
2021/2022122 1 9 1 4 16 12 4 4 25 8 17 21
2022/2023369 19 45 16 32 14 104 0 18 58 11 45 7
2023/2024259 40 8 23 18 31 81 2 5 0 12 3 36
2024/2025141 103 38 0 0 0 0 0 0 0 0 0 0
Totale 1.016